---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-142602"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2021-11-22T23:59:59+00:00"
generated_at: "2026-06-28T06:07:36.559974+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience to acquire Abveris for up to $190M in stock and cash

## Summary
- Total consideration up to $190M: $150M at close (Twist stock + up to $10M cash) plus up to $40M stock tied to 2022 revenue target.
- Stock price per share collared between $106.10 and $129.68 based on 30-day VWAP before closing.
- Abveris adds in vivo antibody discovery platform (DiversimAb mice) to complement Twist's synthetic library and AI capabilities.
- Acquisition expected to bolster Twist's biopharma antibody design, discovery, and screening services for partners and internal pipeline.
- Deal structured as a merger; shares issued in private placement exempt from registration under Section 4(a)(2) and Rule 506.

## SEC filing metadata
- accession: 0001104659-21-142602
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2021-11-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000110465921142602/0001104659-21-142602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000110465921142602/tm2133571d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-142602
- JSON: https://secwatch.observer/filing/0001104659-21-142602.json
- Plain text: https://secwatch.observer/filing/0001104659-21-142602.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.